( MENAFN - GlobeNewsWire - Nasdaq) -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented in an oral and poster presentation at the European Association for the Study of the Liver (EASL) Congress to be held June 5 to 8, 2024 in Milan, Italy. “These data, which are being presented for the first time in a scientific setting, establish pegozafermin as the first FGF21 analog candidate to demonstrate positive, sustained benefits over a 48-week period in patients with advanced MASH,” said Hank Mansbach, Chief Medical Officer of 89bio.
“In addition, these data highlight the observed long-term efficacy, tolerability and sustained improvement in key liver health markers, that we aim to confirm in our ongoing Phase 3 program.” Presentation details are as follows: Abstract Title: Week 48 results from the Phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis Abstract Number: 943 Format : Oral presentat.
